Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.55 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.55 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.55 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.55 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.51 |
| ▸ | PTK2B | Q14289 | 5/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874719 | 0.91 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3887721 | 0.90 | MAPK14 (0.55) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3874647 | 0.90 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3875509 | 0.89 | MAPK14 (0.59) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3877358 | 0.89 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL5826475 | 0.88 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3884809 | 0.88 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3874236 | 0.88 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3880549 | 0.88 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL3879660 | 0.88 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |